{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:10:07Z","timestamp":1792001407828,"version":"4.4.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Survivors of pediatric medulloblastoma experience long-term morbidity associated with the toxic effects of postoperative radiotherapy (RT). Proton RT limits radiation dose to normal tissues thereby reducing side effects of treatment while maintaining high cure rates. However, long-term data on disease outcomes and long-term effects of proton RT remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>One hundred seventy-eight pediatric medulloblastoma patients treated with proton RT between 2002 and 2016 at the Massachusetts General Hospital comprise the cohort of patients who were treated with surgery, radiation therapy, and chemotherapy. We evaluated event-free survival (EFS), overall survival (OS), and local control using the Kaplan-Meier method. The cumulative incidence of brainstem injury and secondary malignancies was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median follow-up was 9.3 years. One hundred fifty-nine patients (89.3%) underwent a gross total resection (GTR). The 10-year OS for the entire cohort, standard-risk (SR), and intermediate\/high-risk (IR\/HR) patients was 79.3%, 86.9%, and 68.9%, respectively. The 10-year EFS for the entire cohort, SR, and IR\/HR cohorts was 73.8%, 79.5%, and 66.2%. The 10-year EFS and OS for patients with GTR\/NTR were 75.3% and 81.0% vs 57.7% and 61.0% for subtotal resection (STR). On univariate analysis, IR\/HR status was associated with inferior EFS, while both anaplastic histology and IR\/HR status were associated with worse OS. The 10-year cumulative incidence of secondary tumors and brainstem injury was 5.6% and 2.1%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this cohort study of pediatric medulloblastoma, proton RT was effective, and disease outcomes were comparable to historically treated photon cohorts. The incidence of secondary malignancies and brainstem injury was low in this cohort with mature follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noab257","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T20:18:00Z","timestamp":1636489080000},"page":"1010-1019","source":"Crossref","is-referenced-by-count":23,"title":["Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy"],"prefix":"10.1093","volume":"24","author":[{"given":"Sujith","family":"Baliga","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gallotto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bajaj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lewy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Weyman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda P","family":"Lawell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beow Y","family":"Yeap","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Ebb","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Caruso","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neuroradiology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J","family":"Tarbell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torunn I","family":"Yock","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital\/Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"2022060115341991300_CIT0001","doi-asserted-by":"crossref","first-page":"iii122","DOI":"10.1093\/neuonc\/now076.104","article-title":"MB-109 preliminary results of COG ACNS0331: a phase III trial of involved field radiotherapy (IFRT) and low dose craniospinal irradiation (LD-CSI) with chemotherapy in average risk medulloblastoma: a report from the Children\u2019s Oncology Group","volume":"18","author":"Michalski","year":"2016","journal-title":"Neuro Oncol"},{"issue":"9","key":"2022060115341991300_CIT0002","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJMoa1510795","article-title":"Reduction in late mortality among 5-year survivors of childhood cancer","volume":"374","author":"Armstrong","year":"2016","journal-title":"N Engl J Med."},{"issue":"3","key":"2022060115341991300_CIT0003","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1677\/ERC-10-0002","article-title":"Endocrine complications in long-term survivors of childhood cancers","volume":"17","author":"Chemaitilly","year":"2010","journal-title":"Endocr Relat Cancer."},{"issue":"13","key":"2022060115341991300_CIT0004","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors","volume":"30","author":"van der Pal","year":"2012","journal-title":"J Clin Oncol."},{"issue":"13","key":"2022060115341991300_CIT0005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jnci\/djp148","article-title":"Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study","volume":"101","author":"Armstrong","year":"2009","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"2022060115341991300_CIT0006","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00130404-200411000-00009","article-title":"Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children","volume":"10","author":"Yuh","year":"2004","journal-title":"Cancer J."},{"issue":"3","key":"2022060115341991300_CIT0007","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1470-2045(15)00167-9","article-title":"Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study","volume":"17","author":"Yock","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022060115341991300_CIT0008","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022060115341991300_CIT0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/neuonc\/nos267","article-title":"Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children\u2019s Oncology Group trial A9961","volume":"15","author":"Packer","year":"2013","journal-title":"Neuro Oncol."},{"issue":"25","key":"2022060115341991300_CIT0010","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","article-title":"Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"24","author":"Packer","year":"2006","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022060115341991300_CIT0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0360-3016(98)00197-7","article-title":"Medulloblastoma: time-dose relationship based on a 30-year review","volume":"42","author":"del Charco","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"2022060115341991300_CIT0012","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J","article-title":"Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival","volume":"61","author":"Hughes","year":"1988","journal-title":"Cancer."},{"issue":"1","key":"2022060115341991300_CIT0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3171\/jns.1981.55.1.0043","article-title":"Radiation treatment for medulloblastoma. A 21-year review","volume":"55","author":"Berry","year":"1981","journal-title":"J Neurosurg."},{"issue":"4","key":"2022060115341991300_CIT0014","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1470-2045(15)00581-1","article-title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis","volume":"17","author":"Thompson","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"2022060115341991300_CIT0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-018-2906-5","article-title":"The clinical importance of medulloblastoma extent of resection: a systematic review","volume":"139","author":"Thompson","year":"2018","journal-title":"J Neurooncol."},{"issue":"33","key":"2022060115341991300_CIT0016","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1200\/JCO.2010.30.2299","article-title":"Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022060115341991300_CIT0017","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-006-0064-x","article-title":"Stratification of medulloblastoma on the basis of histopathological grading","volume":"112","author":"Giangaspero","year":"2006","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2022060115341991300_CIT0018","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijrobp.2007.07.2342","article-title":"Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma","volume":"70","author":"Merchant","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2022060115341991300_CIT0019","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2013.11.239","article-title":"Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses","volume":"88","author":"Sethi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12","key":"2022060115341991300_CIT0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2352-4642(20)30246-7","article-title":"Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study","volume":"4","author":"Hill","year":"2020","journal-title":"Lancet Child Adolesc Health."},{"issue":"24","key":"2022060115341991300_CIT0021","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.20.02730","article-title":"Children\u2019s Oncology Group Phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022060115341991300_CIT0022","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/0284186X.2013.862596","article-title":"Late toxicity following craniospinal radiation for early-stage medulloblastoma","volume":"53","author":"Christopherson","year":"2014","journal-title":"Acta Oncol."},{"issue":"7","key":"2022060115341991300_CIT0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00043426-200110000-00008","article-title":"Prognostic factors and secondary malignancies in childhood medulloblastoma","volume":"23","author":"Stavrou","year":"2001","journal-title":"J Pediatr Hematol Oncol."},{"issue":"7","key":"2022060115341991300_CIT0024","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.ejca.2009.01.015","article-title":"Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT\u201991","volume":"45","author":"Hoff","year":"2009","journal-title":"Eur J Cancer."},{"issue":"3","key":"2022060115341991300_CIT0025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/neuonc\/nou279","article-title":"Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy","volume":"17","author":"Tsui","year":"2015","journal-title":"Neuro Oncol."},{"issue":"8","key":"2022060115341991300_CIT0026","doi-asserted-by":"crossref","first-page":"e27095","DOI":"10.1002\/pbc.27095","article-title":"Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma","volume":"65","author":"Bavle","year":"2018","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2022060115341991300_CIT0027","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.ijrobp.2019.06.603","article-title":"Preliminary report of secondary malignant neoplasm incidence in pediatric patients receiving proton versus photon craniospinal irradiation for medulloblastoma","volume":"105","author":"Paulino","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2022060115341991300_CIT0028","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"2022060115341991300_CIT0029","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline mutations in predisposition genes in pediatric cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"2022060115341991300_CIT0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijrobp.2018.01.013","article-title":"National cancer institute workshop on proton therapy for children: considerations regarding brainstem injury","volume":"101","author":"Haas-Kogan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"2022060115341991300_CIT0031","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3109\/0284186X.2014.957414","article-title":"Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy","volume":"53","author":"Indelicato","year":"2014","journal-title":"Acta Oncol."},{"issue":"3","key":"2022060115341991300_CIT0032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1470-2045(08)70342-5","article-title":"Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study","volume":"10","author":"Merchant","year":"2009","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022060115341991300_CIT0033","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/j.ijrobp.2012.01.061","article-title":"Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors","volume":"83","author":"Murphy","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1107","key":"2022060115341991300_CIT0034","doi-asserted-by":"crossref","first-page":"20190673","DOI":"10.1259\/bjr.20190673","article-title":"An open invitation to join the Pediatric Proton\/Photon Consortium Registry to standardize data collection in pediatric radiation oncology","volume":"93","author":"Lawell","year":"2020","journal-title":"Br J Radiol."},{"key":"2022060115341991300_CIT0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2018.00165","article-title":"An update from the Pediatric Proton Consortium Registry","volume":"8","author":"Hess","year":"2018","journal-title":"Front Oncol."},{"issue":"2","key":"2022060115341991300_CIT0036","doi-asserted-by":"crossref","first-page":"323","DOI":"10.14338\/IJPT.13-00006.1","article-title":"The pediatric proton consortium registry: a multi-institutional collaboration in U.S. proton centers","volume":"1","author":"Kasper","year":"2014","journal-title":"Int J Part Ther"},{"issue":"5","key":"2022060115341991300_CIT0037","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2017.03.033","article-title":"A clarion call for large-scale collaborative studies of pediatric proton therapy","volume":"98","author":"Berrington de Gonzalez","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"2022060115341991300_CIT0038","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer."},{"issue":"1","key":"2022060115341991300_CIT0039","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2016.09.011","article-title":"Patterns of care in proton radiation therapy for pediatric central nervous system malignancies","volume":"97","author":"Odei","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2022060115341991300_CIT0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2018.10.022","article-title":"Patterns of proton therapy use in pediatric cancer management in 2016: an international survey","volume":"132","author":"Journy","year":"2019","journal-title":"Radiother Oncol."},{"issue":"9","key":"2022060115341991300_CIT0041","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamaoncol.2020.2259","article-title":"Race disparities in proton radiotherapy use for cancer treatment in patients enrolled in Children\u2019s Oncology Group trials","volume":"6","author":"Bitterman","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"2022060115341991300_CIT0042","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.19.01706","article-title":"Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma","volume":"38","author":"Kahalley","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab257\/41822547\/noab257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/6\/1010\/43918448\/noab257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/6\/1010\/43918448\/noab257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T15:34:56Z","timestamp":1654097696000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/6\/1010\/6425899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11,12]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab257","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,11,12]]}}}